

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Breast cancer	Chemokine CX3C motif ligand 1 (CX3CL1; fractalkine); HER2 (EGFR2; ErbB2; neu)	<p>Mouse studies suggest inhibiting CX3CL1 could help treat HER2<sup>+</sup> breast cancers. In a transgenic mouse model for <i>Her2<sup>+</sup></i> breast cancer, adenovirus-mediated overexpression of Cx3cl1 increased the number of mammary tumors compared with normal expression. In the mouse model, <i>Cx3cl1</i> knockout delayed tumorigenesis and decreased the number of Her2-driven mammary tumors compared with no knockout. Next steps could include identifying pharmacological inhibitors of CX3CL1.</p> <p><b>SciBX 6(27); doi:10.1038/scibx.2013.677</b>  <b>Published online July 18, 2013</b></p>	Patent and licensing status unavailable	<p>Tardáguila, M. <i>et al. Cancer Res.</i>; published online May 29, 2013; doi:10.1158/0008-5472.CAN-12-3828  <b>Contact:</b> Santos Mañes, National Center for Biotechnology Information, Madrid, Spain                      e-mail: <a href="mailto:smanes@cnb.csic.es">smanes@cnb.csic.es</a></p>